Toward Rapid High-Sensitivity Volume-ConstrainedBiomarker Quantification and Validation using Backscattering Interferometry

摘要

Realizing personalized medicine, which promises to enable early disease detection, efficient diagnostic staging, and therapeutic efficacy monitoring, hinges on biomarker quantification in patient samples. Yet, the lack of a sensitive technology and assay methodology to rapidly validate biomarker candidates continues to be a bottleneck for clinical translation. In our first direct and quantitative comparison of backscattering interferometry (BSI) to fluorescence sensing by ELISA, we show that BSI could aid in overcoming this limitation. The analytical validation study was performed against ELISA for two biomarkers for lung cancer detection: Cyfra 21-1 and Galectin-7. Spiked serum was used for calibration and comparison of analytical figures of merit, followed by analysis of blinded patient samples. Using the ELISA antibody as the probe chemistry in a mix-and-read assay, BSI provided significantly lower detection limits for spiked serum samples with each of the biomarkers. The limit of quantification (LOQ) for Cyrfa-21-1 was measured to be 230 pg/mL for BSI versus 4000 pg/mL for ELISA, and for Galectin-7,it was 13 pg/mL versus 500 pg/mL. The coefficient of variation for5 day, triplicate determinations was <15% for BSI and <10% forELISA. The two techniques correlated well, ranging from 3–29%difference for Cyfra 21-1 in a blinded patient sample analysis. Thelabel-free and free-solution operation of BSI allowed for a significantimprovement in analysis speed, with greater ease, improved LOQ values,and excellent day-to-day reproducibility. In this unoptimized format,BSI required 5.5-fold less sample quantity needed for ELISA (a 10point calibration curve measured in triplicate required 36 μLof serum for BSI vs 200 μL for ELISA). The results indicatethat the BSI platform can enable rapid, sensitive analytical validationof serum biomarkers and should significantly impact the validationbottleneck of biomarkers.